Events
Stay informed on our events
Upcoming Events
AACR Annual Meeting 2025, April 25-30, Chicago
We will be attending the AACR Annual Meeting, April 25-30, 2025, taking place at the McCormick Place Convention Center, Chicago, Illinois. Don't miss our poster presentations: Title: 5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and identifies loss of AR signaling in NEPC and DNPC (poster presentation from UCSF...
Previous Events
2025 ACMG Annual Clinical Genetics Meeting | March 18-22, Los Angeles
ClearNote Health will be attending the 2025 ACMG Annual Clinical Genetics Meeting, March 18-22, Los Angeles. Don't miss our poster presentation: Presenter: Shimul Chowdhury, PhD, FACMG, CGMB, Vice President of Laboratory Operations Submission ID: 625881...
TRI-CON 2025 | March 11-13, San Diego
ClearNote Health will be at TRI-CON 2025. Meet us at booth 3 and learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient...
American Society of Clinical Oncology (ASCO) GU25 | February 13-15
ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) GU25 Symposium, February 13-15, San Francisco. Connect with Gulfem to learn more about ClearNote Health's...
Society for Immunotherapy of Cancer | Nov 6 – 10, 2024
ClearNote presented a poster entitled: “Cell-type specific signatures in plasma cell-free DNA 5-hydroxymethylome enables cancer detection and response monitoring in non-small cell lung cancer patients undergoing anti-PD-1 treatment.”
AACR Special Conference on Liquid Biopsy | November 12 -16, 2024
ClearNote presented a poster entitled: “Cancer-induced epigenomic changes in circulating immune cells enable breast, colorectal and lung cancer detection.”
CGA-IGC – Hereditary Gastrointestinal Cancer | Nov 14-16, 2024
ClearNote attended with booth (#6).
ISPOR Europe | Nov 17-20, 2024
ClearNote Health presented findings from a clinico-economic analysis of its Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer”...
14th World CB & CDx Boston Summit | September 3rd – 6th, 2024
ClearNote Health attended the 14th World CB & CDx Boston Summit. ... Virtuoso represents a paradigm shift in drug development, offering non-invasive testing, longitudinal research capabilities, and individualized patient epigenomics to reveal critical biological...
American Diabetes Association 84th Scientific Sessions | June 21st – 24th, 2024
ADA took place in Orlando, FL., June 21–24, 2024.
American Society of Clinical Oncology (ASCO) | May 31st – June 4th, 2024
The American Society of Clinical Oncology (ASCO), took place in Chicago, May 31st - June 4th, 2024. We were present at our partner Personalis' booth #30149. If you missed us, contact us to learn more about how our proprietary, non-invasive 5hmC epigenomic platform...